Free Trial

Apyx Medical (APYX) Competitors

Apyx Medical logo
$4.61 -0.25 (-5.14%)
Closing price 04:00 PM Eastern
Extended Trading
$4.63 +0.02 (+0.43%)
As of 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

APYX vs. BVS, BWAY, SIBN, SGP, and BBNX

Should you buy Apyx Medical stock or one of its competitors? MarketBeat compares Apyx Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Apyx Medical include Bioventus (BVS), Brainsway (BWAY), SiBone (SIBN), Spyglass Pharma (SGP), and Beta Bionics (BBNX). These companies are all part of the "medical equipment" industry.

How does Apyx Medical compare to Bioventus?

Apyx Medical (NASDAQ:APYX) and Bioventus (NASDAQ:BVS) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Apyx Medical presently has a consensus price target of $6.50, suggesting a potential upside of 41.00%. Bioventus has a consensus price target of $14.00, suggesting a potential upside of 54.70%. Given Bioventus' stronger consensus rating and higher probable upside, analysts plainly believe Bioventus is more favorable than Apyx Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apyx Medical
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.67
Bioventus
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00

In the previous week, Bioventus had 3 more articles in the media than Apyx Medical. MarketBeat recorded 4 mentions for Bioventus and 1 mentions for Apyx Medical. Apyx Medical's average media sentiment score of 1.89 beat Bioventus' score of 1.00 indicating that Apyx Medical is being referred to more favorably in the media.

Company Overall Sentiment
Apyx Medical Very Positive
Bioventus Positive

Bioventus has a net margin of 4.94% compared to Apyx Medical's net margin of -16.40%. Bioventus' return on equity of 29.97% beat Apyx Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Apyx Medical-16.40% -88.47% -14.94%
Bioventus 4.94%29.97%9.52%

Apyx Medical has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market. Comparatively, Bioventus has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

55.3% of Apyx Medical shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 15.2% of Apyx Medical shares are owned by insiders. Comparatively, 33.0% of Bioventus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bioventus has higher revenue and earnings than Apyx Medical. Apyx Medical is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apyx Medical$52.84M3.65-$11.21M-$0.22N/A
Bioventus$568.09M1.33$22.73M$0.4122.07

Summary

Bioventus beats Apyx Medical on 12 of the 15 factors compared between the two stocks.

How does Apyx Medical compare to Brainsway?

Apyx Medical (NASDAQ:APYX) and Brainsway (NASDAQ:BWAY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

In the previous week, Brainsway had 2 more articles in the media than Apyx Medical. MarketBeat recorded 3 mentions for Brainsway and 1 mentions for Apyx Medical. Apyx Medical's average media sentiment score of 1.89 beat Brainsway's score of 0.62 indicating that Apyx Medical is being referred to more favorably in the media.

Company Overall Sentiment
Apyx Medical Very Positive
Brainsway Positive

Brainsway has a net margin of 15.68% compared to Apyx Medical's net margin of -16.40%. Brainsway's return on equity of 12.28% beat Apyx Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Apyx Medical-16.40% -88.47% -14.94%
Brainsway 15.68%12.28%7.75%

Brainsway has lower revenue, but higher earnings than Apyx Medical. Apyx Medical is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apyx Medical$52.84M3.65-$11.21M-$0.22N/A
Brainsway$52.22M10.86$7.57M$0.3540.43

Apyx Medical currently has a consensus target price of $6.50, suggesting a potential upside of 41.00%. Brainsway has a consensus target price of $16.00, suggesting a potential upside of 13.07%. Given Apyx Medical's higher probable upside, equities research analysts clearly believe Apyx Medical is more favorable than Brainsway.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apyx Medical
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.67
Brainsway
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

55.3% of Apyx Medical shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 15.2% of Apyx Medical shares are held by insiders. Comparatively, 19.0% of Brainsway shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Apyx Medical has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

Summary

Brainsway beats Apyx Medical on 10 of the 16 factors compared between the two stocks.

How does Apyx Medical compare to SiBone?

Apyx Medical (NASDAQ:APYX) and SiBone (NASDAQ:SIBN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

SiBone has a net margin of -8.10% compared to Apyx Medical's net margin of -16.40%. SiBone's return on equity of -9.56% beat Apyx Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Apyx Medical-16.40% -88.47% -14.94%
SiBone -8.10%-9.56%-7.06%

Apyx Medical has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, SiBone has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market.

55.3% of Apyx Medical shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 15.2% of Apyx Medical shares are held by company insiders. Comparatively, 3.9% of SiBone shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Apyx Medical currently has a consensus target price of $6.50, suggesting a potential upside of 41.00%. SiBone has a consensus target price of $23.00, suggesting a potential upside of 49.64%. Given SiBone's stronger consensus rating and higher probable upside, analysts plainly believe SiBone is more favorable than Apyx Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apyx Medical
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.67
SiBone
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

Apyx Medical has higher earnings, but lower revenue than SiBone. SiBone is trading at a lower price-to-earnings ratio than Apyx Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apyx Medical$52.84M3.65-$11.21M-$0.22N/A
SiBone$200.93M3.39-$18.90M-$0.39N/A

In the previous week, SiBone had 4 more articles in the media than Apyx Medical. MarketBeat recorded 5 mentions for SiBone and 1 mentions for Apyx Medical. Apyx Medical's average media sentiment score of 1.89 beat SiBone's score of 0.45 indicating that Apyx Medical is being referred to more favorably in the media.

Company Overall Sentiment
Apyx Medical Very Positive
SiBone Neutral

Summary

SiBone beats Apyx Medical on 9 of the 17 factors compared between the two stocks.

How does Apyx Medical compare to Spyglass Pharma?

Spyglass Pharma (NASDAQ:SGP) and Apyx Medical (NASDAQ:APYX) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

In the previous week, Spyglass Pharma and Spyglass Pharma both had 1 articles in the media. Apyx Medical's average media sentiment score of 1.89 beat Spyglass Pharma's score of 1.87 indicating that Apyx Medical is being referred to more favorably in the news media.

Company Overall Sentiment
Spyglass Pharma Very Positive
Apyx Medical Very Positive

55.3% of Apyx Medical shares are owned by institutional investors. 15.2% of Apyx Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Spyglass Pharma currently has a consensus price target of $45.00, suggesting a potential upside of 150.42%. Apyx Medical has a consensus price target of $6.50, suggesting a potential upside of 41.00%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Spyglass Pharma is more favorable than Apyx Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spyglass Pharma
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
Apyx Medical
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.67

Spyglass Pharma has higher earnings, but lower revenue than Apyx Medical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spyglass PharmaN/AN/AN/AN/AN/A
Apyx Medical$52.84M3.65-$11.21M-$0.22N/A

Spyglass Pharma has a net margin of 0.00% compared to Apyx Medical's net margin of -16.40%. Spyglass Pharma's return on equity of 0.00% beat Apyx Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Spyglass PharmaN/A N/A N/A
Apyx Medical -16.40%-88.47%-14.94%

Summary

Spyglass Pharma beats Apyx Medical on 6 of the 11 factors compared between the two stocks.

How does Apyx Medical compare to Beta Bionics?

Beta Bionics (NASDAQ:BBNX) and Apyx Medical (NASDAQ:APYX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Beta Bionics presently has a consensus target price of $19.70, suggesting a potential upside of 43.59%. Apyx Medical has a consensus target price of $6.50, suggesting a potential upside of 41.00%. Given Beta Bionics' higher possible upside, equities research analysts clearly believe Beta Bionics is more favorable than Apyx Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beta Bionics
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.64
Apyx Medical
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.67

55.3% of Apyx Medical shares are owned by institutional investors. 5.3% of Beta Bionics shares are owned by company insiders. Comparatively, 15.2% of Apyx Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Beta Bionics had 10 more articles in the media than Apyx Medical. MarketBeat recorded 11 mentions for Beta Bionics and 1 mentions for Apyx Medical. Apyx Medical's average media sentiment score of 1.89 beat Beta Bionics' score of 0.08 indicating that Apyx Medical is being referred to more favorably in the news media.

Company Overall Sentiment
Beta Bionics Neutral
Apyx Medical Very Positive

Apyx Medical has a net margin of -16.40% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat Apyx Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Beta Bionics-60.27% -23.00% -20.55%
Apyx Medical -16.40%-88.47%-14.94%

Beta Bionics has a beta of 3.4, meaning that its stock price is 240% more volatile than the broader market. Comparatively, Apyx Medical has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market.

Apyx Medical has lower revenue, but higher earnings than Beta Bionics. Apyx Medical is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beta Bionics$100.25M6.10-$73.20M-$1.51N/A
Apyx Medical$52.84M3.65-$11.21M-$0.22N/A

Summary

Beta Bionics and Apyx Medical tied by winning 8 of the 16 factors compared between the two stocks.

Get Apyx Medical News Delivered to You Automatically

Sign up to receive the latest news and ratings for APYX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APYX vs. The Competition

MetricApyx MedicalMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$193.02M$8.16B$6.43B$11.71B
Dividend YieldN/A2.51%2.67%5.55%
P/E Ratio-20.9516.1024.4623.62
Price / Sales3.656.75500.50105.27
Price / CashN/A17.1542.3656.09
Price / Book11.823.5410.436.70
Net Income-$11.21M$225.32M$3.56B$337.26M
7 Day Performance21.64%-0.12%-1.39%-1.41%
1 Month Performance25.61%1.43%0.86%1.15%
1 Year Performance153.30%-4.31%19.42%22.61%

Apyx Medical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APYX
Apyx Medical
2.5857 of 5 stars
$4.61
-5.1%
$6.50
+41.0%
+180.9%$193.02M$52.84MN/A270
BVS
Bioventus
4.3284 of 5 stars
$8.11
+2.3%
$14.00
+72.6%
N/A$662.43M$568.09M19.781,200
BWAY
Brainsway
2.9479 of 5 stars
$14.56
-5.7%
$16.00
+9.9%
+162.1%$618.38M$52.22M41.60120
SIBN
SiBone
2.323 of 5 stars
$14.01
+1.0%
$23.00
+64.2%
-17.7%$615.12M$200.93MN/A350
SGP
Spyglass Pharma
N/A$18.36
+0.2%
$45.00
+145.1%
N/A$613.83MN/AN/A65

Related Companies and Tools


This page (NASDAQ:APYX) was last updated on 6/10/2026 by MarketBeat.com Staff.
From Our Partners